22200-50-6

Basic information

• Product Name: 7-IODO-4-CHLOROQUINOLINE
• Synonyms: 7-IODO-4-CHLOROQUINOLINE;BUTTPARK 89\09-06
• CAS NO: 22200-50-6
• Molecular Formula: C₉H₅ClIN
• Molecular Weight: 289.5
• Mol File: 22200-50-6.mol

Chemical Properties

• Melting Point: 101-102 °C
• Boiling Point: 338.368 °C at 760 mmHg
• Flash Point: 158.439 °C
• Appearance: /
• Density: 1.92 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.727
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.05±0.27(Predicted)
• CAS DataBase Reference: 7-IODO-4-CHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-IODO-4-CHLOROQUINOLINE(22200-50-6)
• EPA Substance Registry System: 7-IODO-4-CHLOROQUINOLINE(22200-50-6)

Safety Data

• Hazardous Substances Data: 22200-50-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-IODO-4-CHLOROQUINOLINE is used as a key intermediate in the synthesis of antimalarial drugs, specifically targeting the Plasmodium species responsible for causing malaria. Its antiparasitic properties make it a promising candidate for the development of new treatments against this life-threatening disease.
Used in Antimicrobial Applications:
7-IODO-4-CHLOROQUINOLINE is used as an antimicrobial agent for its potential to inhibit the growth of various microorganisms. Its broad-spectrum activity makes it a valuable compound in the development of new antibiotics and antifungal agents to combat drug-resistant infections.
Used in Drug Discovery and Development:
7-IODO-4-CHLOROQUINOLINE is used as a versatile building block in organic synthesis for the development of various bioactive compounds with potential therapeutic applications. Its unique chemical structure allows for the creation of novel compounds with improved pharmacological properties and therapeutic efficacy.
Used in Research and Development:
7-IODO-4-CHLOROQUINOLINE is used as a research compound to study its potential antiparasitic and antimicrobial properties, as well as its potential use in the treatment of other infectious diseases. This research helps to advance our understanding of the compound's mechanism of action and its potential applications in medicine.

InChI:InChI=1/C9H5ClIN/c10-8-3-4-12-9-5-6(11)1-2-7(8)9/h1-5H

Upstream product

• 22297-71-8 7-iodo-quinolin-4-ol 
• 22200-49-3 4-hydroxy-7-iodo-quinoline-3-carboxylic acid 
• 22200-48-2 4-hydroxy-7-iodo-quinoline-3-carboxylic acid ethyl ester 
• 22200-47-1 diethyl 2-(((3-iodophenyl)amino)methylene)malonate 
• 626-01-7 3-Iodoaniline 
• 134785-83-4 4-hydroxy-7-iodo-quinoline-2-carboxylic acid 
• 153952-04-6 4-hydroxy-7-iodo-quinoline-2-carboxylic acid ethyl ester 

Downstream Products

• 17127-81-0 4-(3-Dimethylaminopropylamino)-7-iodchinolin 
• 1062589-64-3 C₁₄H₉ClN₂ 
• 1062751-74-9 C₁₅H₉ClFIN₂O 
• 1062589-83-6 C₁₅H₉ClFIN₂O*ClH 
• 231277-94-4 (4-phenoxyphenyl)-(7-((4-(2-methanesulphonyl)ethylaminomethyl)thiazol-5-yl)-quinolin-4-yl)amine 
• 81764-16-1 4-chloro-8-aminoquinoline 
• 1450909-21-3 (1-benzyl-7-trimethylstannanyl-1H-quinolin-4-ylidene)-pentyl-amine 
• 1450909-20-2 (1-benzyl-7-iodo-1H-quinolin-4-ylidene)-pentyl-amine 

Relevant articles and documents

Synthesis and evaluation of a 125I-labeled iminodihydroquinoline-derived tracer for imaging of voltage-gated sodium channels

In vivo imaging of voltage-gated sodium channels (VGSCs) can potentially provide insights into the activation of neuronal pathways and aid the diagnosis of a number of neurological diseases. The iminodihydroquinoline WIN17317-3 is one of the most potent s

Compounds and Methods of Treatment

A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.

NOVEL QUINOLINE DERIVATIVES

The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

Structure-activity relationships for antiplasmodial activity among 7- substituted 4-aminoquinolines

Aminoquinolines (AQs) with diaminoalkane side chains (-HNRNEt2) shorter or longer than the isopentyl side chain [-HNCHMe(CH2)3NEt2] of chloroquine are active against both chloroquine-susceptible and -resistant Plasmodium falciparum. (De, D.; et al. Am. J. Trop. Med. Hyg. 1996, 55, 579-583). In the studies reported here, we examined structure-activity relationships (SARs) among AQs with different N,N-diethyldiaminoalkane side chains and different substituents at the 7-position occupied by Cl in chloroquine. 7-Iodo- and 7- bromo-AQs with diaminoalkane side chains [-HN(CH2)2NEt2, -HN(CH2)3NEt2, or -HNCHMeCH2NEt2] were as active as the corresponding 7-chloro-AQs against both chloroquine-susceptible and -resistant P. falciparum (IC50s of 3-12 nM). In contrast, with one exception, 7-fluoro-AQs and 7-trifluoromethyl-AQs were less active against chloroquine-susceptible P. falciparum (IC50s of 15-50 nM) and substantially less active against chloroquine-resistant P. falciparum (IC50s of 18-500 nM). Furthermore, most 7-OMe-AQs were inactive against both chloroquine-susceptible (IC50s of 17-150 nM) and -resistant P. falciparum (IC50s of 90-3000 nM).

SYNTHESIS OF DERIVATIVES OF 7-IODO-4-AMINOQUINOLINES

7-Iodo- and 7,8-diiodo-4-(3-dimethylaminopropylamino)quinolines and 7-iodo-4-(3-dipropylaminopropylamino)- and 7-iodo-4-(3-diallylaminopropylamino)quinoline were obtained by the reaction of 7-iodo- and 7,8-diiodo-4-chloroquinolines with the the corresponding diamines.The catalytic hydrogenation of 7-iodo-4-(3-diallylaminopropylamino)quinoline at normal pressure leads to 7-iodo-4-(3-dipropylaminopropylamino)quinoline.